🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are increasing around the world, with estimates suggesting more than 82 million instances per year. Notably increased rates are seen in Africa and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the face of rising global incidence, increasing antimicrobial resistance and the very limited available drugs currently available.”

Health officials are increasingly worried about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Testing Results and Global Access

Based on findings released by a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This establishes an equal footing with the current standard treatment, which involves a dual-drug approach. The research included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians on the front lines have expressed hope. Access to a easy-to-administer therapy of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as essential to lessen the impact of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.